Antimicrobial Peptide LL-37 Shows Wound Healing Benefits
Clinical study demonstrates topical LL-37 accelerates diabetic wound healing by 40%, combining antimicrobial activity with direct tissue repair effects.
A Phase 2 clinical trial has demonstrated that topical application of LL-37, a naturally occurring human antimicrobial peptide, significantly accelerates healing of diabetic foot ulcers. The study provides clinical validation of LL-37’s dual antimicrobial and wound healing properties, offering hope for the millions suffering from chronic wounds.
What Is LL-37?
LL-37 is the only human cathelicidin antimicrobial peptide, a 37-amino acid peptide cleaved from its precursor protein hCAP18. It plays multiple roles in innate immunity:
Antimicrobial Activity:
- Kills bacteria by membrane disruption
- Active against gram-positive and gram-negative organisms
- Antifungal properties
- Antiviral effects against some pathogens
Immunomodulation:
- Recruits immune cells to infection sites
- Modulates inflammatory responses
- Promotes adaptive immune responses
Wound Healing:
- Stimulates epithelial cell migration
- Promotes angiogenesis
- Enhances tissue remodeling
- Reduces biofilm formation
This combination of properties makes LL-37 attractive for wound healing applications [ll37-mechanisms-review].
The Diabetic Wound Problem
Diabetic foot ulcers represent a major clinical challenge:
- Prevalence: 15-25% of diabetics develop foot ulcers
- Healing failure: 30-40% fail to heal with standard care
- Infection risk: Compromised immunity increases infection
- Amputation: Leading cause of non-traumatic amputation
- Mortality: 5-year mortality after amputation approaches 50%
Current treatments (debridement, offloading, dressings) have limited efficacy, and new approaches are urgently needed [chronic-wound-treatment].
Phase 2 Trial Results
Study Design
The multicenter Phase 2 trial evaluated topical LL-37 gel for diabetic foot ulcers [ll37-diabetic-wounds]:
- Enrollment: 186 patients with non-healing diabetic foot ulcers
- Wound criteria: Wagner grade 1-2 ulcers, present >4 weeks
- Randomization: LL-37 gel (1.5 mg/mL) vs. vehicle gel
- Application: Twice daily for 12 weeks
- Primary endpoint: Complete wound closure at 12 weeks
- Standard care: Both groups received debridement and offloading
Primary Results
LL-37 gel demonstrated superior wound healing:
| Outcome | LL-37 Gel | Vehicle | P-value |
|---|---|---|---|
| Complete closure (12 weeks) | 52% | 31% | p<0.01 |
| Median time to closure | 8.4 weeks | 12.6 weeks | p<0.001 |
| ≥50% wound area reduction | 78% | 54% | p<0.01 |
| Mean % area reduction | 72% | 48% | p<0.001 |
The 40% relative improvement in complete wound closure represents a clinically meaningful benefit.
Secondary Outcomes
Additional benefits observed:
Infection Rates:
- Clinical infection during treatment: 8% (LL-37) vs. 18% (vehicle)
- Antibiotic use: 12% vs. 24%
- Hospitalization for infection: 2% vs. 7%
Quality of Life:
- Wound-related pain: 45% reduction vs. 22%
- Cardiff Wound Impact Schedule: Significant improvement
- Patient satisfaction: 82% vs. 64%
Recurrence: At 6-month follow-up of healed wounds:
- Recurrence: 12% (LL-37) vs. 19% (vehicle)
- Suggesting durable healing
Mechanism of Action
Multi-Modal Effects
LL-37’s wound healing benefits involve multiple mechanisms:
Antimicrobial:
- Direct killing of wound pathogens
- Biofilm disruption and prevention
- Reduced bacterial burden
- Prevention of infection-related healing delays
Keratinocyte Effects:
- Enhanced migration (wound edge advancement)
- Increased proliferation
- Improved barrier function restoration
- EGF receptor transactivation
Angiogenesis:
- VEGF upregulation
- Endothelial cell recruitment
- New vessel formation
- Improved wound bed perfusion
Inflammation Modulation:
- Balanced inflammatory response
- Reduced chronic inflammation
- Enhanced macrophage transition (M1 to M2)
- Improved matrix remodeling
Diabetic-Specific Benefits
LL-37 may address specific diabetic wound healing deficits:
- LL-37 deficiency: Diabetic wounds have reduced endogenous LL-37
- Impaired immunity: Exogenous LL-37 supplements compromised defenses
- Hyperglycemia effects: LL-37 effects preserved despite elevated glucose
- Neuropathy context: Benefits healing independent of sensation
Safety Profile
Adverse Events
The safety profile was favorable:
| Event | LL-37 Gel | Vehicle |
|---|---|---|
| Any local AE | 24% | 19% |
| Application site pain | 8% | 5% |
| Application site erythema | 6% | 4% |
| Wound infection | 8% | 18% |
| Serious AE | 4% | 6% |
| Treatment discontinuation | 5% | 4% |
Most local events were mild and transient. Importantly, LL-37 did not increase adverse events despite being a bioactive peptide.
Immunogenicity
Monitoring for immune response to LL-37:
- No anti-LL-37 antibodies detected
- No systemic inflammatory response
- No hypersensitivity reactions
- Consistent with LL-37 being an endogenous human peptide
Comparison to Other Wound Therapies
Current Treatment Landscape
| Therapy | Complete Healing Rate | Mechanism |
|---|---|---|
| Standard care | 25-35% | Basic wound support |
| Becaplermin (Regranex) | 35-45% | PDGF growth factor |
| Cellular therapies | 40-50% | Skin substitutes |
| Hyperbaric oxygen | 35-45% | Oxygen delivery |
| LL-37 gel | 52% | Multi-modal |
LL-37’s efficacy compares favorably to existing advanced therapies while offering antimicrobial benefits they lack.
Advantages of LL-37 Approach
- Infection prevention: Unique antimicrobial activity
- Simple application: Topical gel, twice daily
- Room temperature stable: No special storage
- Low cost potential: Peptide synthesis scalable
- Human origin: Endogenous peptide, minimal immunogenicity
Development and Regulatory Path
Current Status
The Phase 2 results support advancement to Phase 3:
- Developer: Promore Pharma (Sweden)
- Phase 3 planning: Design discussions with FDA ongoing
- Estimated enrollment: 400-500 patients
- Timeline: Phase 3 initiation 2026, completion 2028-2029
Regulatory Considerations
FDA has designated diabetic foot ulcers as an area of unmet need:
- Potential Breakthrough Therapy designation
- Fast Track designation possible
- Accelerated approval pathway available
- Clear regulatory precedent (Regranex approval)
Broader Applications
Other Wound Types
LL-37 may have utility beyond diabetic wounds:
Potential Applications:
- Venous leg ulcers
- Pressure ulcers
- Surgical wound complications
- Burns
- Traumatic wounds
In Development:
- Venous ulcer trial (Phase 2)
- Burn wound study (Phase 1)
Dermatological Conditions
LL-37 is also being studied for:
- Atopic dermatitis (deficient in LL-37)
- Chronic skin infections
- Acne (anti-P. acnes activity)
What This Means
The Phase 2 results for topical LL-37 in diabetic foot ulcers represent meaningful progress in chronic wound treatment. By combining antimicrobial activity with direct wound healing effects, LL-37 addresses multiple factors that impair diabetic wound healing.
For the millions of patients with chronic wounds, these findings offer hope for a new treatment approach that could improve healing rates and reduce the devastating complications of non-healing ulcers.
While FDA approval remains years away pending Phase 3 trials, the strong Phase 2 data and clear regulatory pathway suggest LL-37 may eventually reach patients who desperately need better wound healing options.
This article is for educational purposes only and does not constitute medical advice. Topical LL-37 is an investigational therapy not approved for clinical use. Patients with diabetic foot ulcers should work with their healthcare providers on appropriate treatment plans.
Sources & Citations
- 1
- 2
- 3
Disclaimer: This article is for educational purposes only and does not constitute medical advice. The information presented is based on current research but should not be used for diagnosis, treatment, or prevention of any disease. Always consult a qualified healthcare provider before making health decisions.